When is the next results date for Ipca Labs?

No Upcoming Board Meetings

Has Ipca Labs declared dividend?

Ipca Laboratories Ltd has declared a 200% dividend, amounting to ₹2 per share, with an ex-date of November 27, 2024. The dividend yield is 0.29%, and the company has shown strong total returns over various periods, particularly in the long term.

Ipca Laboratories Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 2 per share<BR>- Ex-date: Nov-27-2024<BR><BR>Dividend Yield: 0.29%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -9.73%, the dividend return was 0%, resulting in a total return of -9.73%.<BR><BR>Over the past year, the price return was 19.48%, the dividend return was 0.34%, leading to a total return of 19.82%.<BR><BR>In the 2-year period, the price return was 85.62%, the dividend return was 0.82%, culminating in a total return of 86.44%.<BR><BR>For the 3-year period, the price return was 60.69%, the dividend return was 1.12%, resulting in a total return of 61.81%.<BR><BR>In the last 4 years, the price return was 34.76%, the dividend return was 1.79%, leading to a total return of 36.55%.<BR><BR>Over the past 5 years, the price return was 84.96%, the dividend return was 3.14%, resulting in a total return of 88.1%.<BR><BR>Overall, Ipca Laboratories Ltd has declared a significant dividend while also demonstrating strong total returns over various periods, particularly in the longer term. The dividend yield remains modest, indicating a balanced approach between price appreciation and dividend distribution.

Who are the peers of the Ipca Labs?

Ipca Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Laurus Labs, Ajanta Pharma, Piramal Pharma, Gland Pharma, and Cohance Life. In terms of management risk, growth, and capital structure, they vary, with Divi's Lab showing the highest 1-year return at 51.96% and Gland Pharma the lowest at -11.87%.

Peers: The peers of Ipca Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Laurus Labs, Ajanta Pharma, Piramal Pharma, Gland Pharma, and Cohance Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ajanta Pharma and Cohance Life, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ipca Labs, Laurus Labs, Gland Pharma, and Piramal Pharma, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is noted at Ipca Labs, Laurus Labs, and the rest. Below Average growth is seen at Divi's Lab., Torrent Pharma, Ajanta Pharma, and Gland Pharma. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Ipca Labs, and Ajanta Pharma, while Good capital structure is found at Torrent Pharma, and Average at Laurus Labs and Piramal Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Gland Pharma at -11.87%. Ipca Labs has a 1-year return of 24.28%, which is higher than Gland Pharma but lower than Divi's Lab. Additionally, the peers with negative six-month returns include Piramal Pharma, Gland Pharma, and Cohance Life.

Who are in the management team of Ipca Labs?

As of March 2023, the management team of Ipca Labs includes Premchand Godha (Chairman), A K Jain (Managing Director & CFO), Pranay Godha (CEO), and several independent directors, overseeing the company's operations and strategy.

As of March 2023, the management team of Ipca Labs includes the following individuals:<BR><BR>1. **Premchand Godha** - Chairman / Executive Director<BR>2. **A K Jain** - Managing Director and Joint Managing Director & CFO<BR>3. **Pranay Godha** - Executive Director / Managing Director / CEO / Promoter<BR>4. **Prashant Godha** - Executive Director<BR>5. **Anand T Kusre** - Independent Director and Independent Non-Executive Director<BR>6. **Manisha Premnath** - Independent Director and Independent Non-Executive Director<BR>7. **Kamal Kishore Seth** - Independent Director and Independent Non-Executive Director<BR>8. **Narendra Mairpady** - Independent Director and Independent Non-Executive Director<BR>9. **Harish P Kamath** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Ipca Labs do?

Ipca Laboratories Ltd is a large integrated pharmaceutical company that manufactures over 350 formulations and 80 active pharmaceutical ingredients. As of March 2025, it reported net sales of ₹22,467 Cr and a net profit of ₹678 Cr, with a market cap of ₹37,404 Cr.

Overview:<BR>Ipca Laboratories Ltd is a fully integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs), operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>Ipca Laboratories was incorporated on 19 October 1949 under the name 'The Indian Pharmaceutical Combine Association Limited.' The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 22,467 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 678 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 37,404 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 44.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.27% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 12.13% <BR>Price to Book: 5.35 <BR><BR>Contact Details:<BR>Address: 48 Kandivli Industrial Estate, Kandivli (West) Mumbai Maharashtra : 400067 <BR>Tel: 91-22-66474444 <BR>Email: ipca@ipca.co.in/investors@ipca.com <BR>Website: http://www.ipca.com

Who are the top shareholders of the Ipca Labs?

The top shareholders of Ipca Labs include promoters holding 21.47%, mutual funds with a collective 29.63% (led by HDFC Mid-cap Opportunities Fund at 8.47%), foreign institutional investors at 10.76%, and individual investors at 6.81%.

The top shareholders of Ipca Labs include a mix of promoters, mutual funds, and foreign institutional investors. The majority shareholders are the promoters, with Kaygee Investments Private Limited holding the largest share at 21.47%. Mutual funds collectively hold 29.63% through 33 schemes, with HDFC Mutual Fund's HDFC Mid-cap Opportunities Fund being the highest public shareholder at 8.47%. Additionally, foreign institutional investors (FIIs) hold 10.76% of the company, while individual investors account for 6.81%.

How big is Ipca Labs?

As of 24th July, Ipca Laboratories Ltd has a market capitalization of 37,170.00 Cr, with recent net sales of 8,939.59 Cr and net profit of 737.68 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Ipca Laboratories Ltd has a market capitalization of 37,170.00 Cr, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 8,939.59 Cr, while the sum of Net Profit for the same period is 737.68 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 6,948.45 Cr and Total Assets totaling 11,743.63 Cr.

Are Ipca Labs latest results good or bad?

Ipca Laboratories' latest results are generally positive, with a 58.12% year-on-year increase in Profit After Tax and a 243.87% quarter-on-quarter growth in net profit, indicating strong performance. However, concerns about the sustainability of non-operating income suggest a need for cautious optimism.

Ipca Laboratories' latest results indicate a generally positive performance, showcasing significant growth in key financial metrics. The Profit After Tax (PAT) for the last six months has reached Rs 406.41 crore, which is a remarkable year-on-year increase of 58.12%. This suggests a strong near-term outlook for the company.<BR><BR>In terms of quarterly performance, the net profit for the quarter ending June 2025 saw an impressive QoQ growth of 243.87%, recovering from a decline in the previous quarter. Additionally, net sales grew by 2.77% compared to the prior quarter, indicating a positive trend in revenue generation.<BR><BR>Operating cash flow has also reached an annual high of Rs 1,321.32 crore, reflecting consistent growth over the past three years, which is a strong indicator of effective cash management and operational efficiency.<BR><BR>However, there are some concerns regarding the sustainability of the company's financial health, particularly with the increase in non-operating income, which may not be as reliable as income generated from core business activities.<BR><BR>Overall, while there are mixed signals, the substantial growth in PAT and net profit suggests that Ipca Laboratories is performing well, making the latest results more favorable than unfavorable.

Is Ipca Labs overvalued or undervalued?

As of September 2, 2025, Ipca Labs is fairly valued with a PE ratio of 39.19, an EV to EBITDA of 19.94, and a PEG ratio of 0.66, making it an attractive investment compared to its peers, Sun Pharma and Divi's Lab, which are considered expensive.

As of 2 September 2025, the valuation grade for Ipca Labs has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 39.19, an EV to EBITDA of 19.94, and a PEG ratio of 0.66, indicating a relatively attractive growth potential compared to its price.<BR><BR>In comparison to its peers, Ipca Labs stands out with a fair valuation while Sun Pharma is considered expensive with a PE of 32.69 and Divi's Lab is very expensive with a PE of 70.48. Notably, the company's return over the past year has been slightly better than the Sensex, which aligns with its fair valuation status. Overall, Ipca Labs presents a balanced investment opportunity within the pharmaceuticals and biotechnology sector.

How has been the historical performance of Ipca Labs?

Ipca Labs has exhibited consistent growth in net sales and profitability, with net sales increasing from ₹3,773.18 Cr in Mar'19 to ₹8,939.59 Cr in Mar'25, and profit after tax rising from ₹444.03 Cr to ₹787.53 Cr during the same period. The company's financial performance reflects resilience, with improved operating profit and positive cash flow.

Answer:<BR>The historical performance of Ipca Labs shows a consistent growth trajectory in net sales and profitability over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Ipca Labs has demonstrated significant growth in net sales, rising from 3,773.18 Cr in Mar'19 to 8,939.59 Cr in Mar'25. This upward trend is reflected in total operating income, which also increased from 3,773.18 Cr in Mar'19 to 8,939.59 Cr in Mar'25. The total expenditure has risen correspondingly, from 3,081.30 Cr in Mar'19 to 7,213.45 Cr in Mar'25, yet the operating profit (PBDIT) has shown improvement, climbing from 749.56 Cr in Mar'19 to 1,818.94 Cr in Mar'25. Profit before tax has also increased from 548.27 Cr in Mar'19 to 1,131.14 Cr in Mar'25, while profit after tax reached 787.53 Cr in Mar'25, up from 444.03 Cr in Mar'19. The earnings per share (EPS) rose from 35.21 in Mar'19 to 29.08 in Mar'25, indicating a strong performance despite fluctuations in profitability. The company's total assets have expanded from 5,257.82 Cr in Mar'20 to 11,743.63 Cr in Mar'25, with total liabilities increasing from 5,257.82 Cr to 11,743.63 Cr during the same period. Cash flow from operating activities has improved, reaching 1,321.00 Cr in Mar'25 compared to 570.00 Cr in Mar'20, while net cash inflow turned positive at 168.00 Cr in Mar'25 after a negative outflow in the previous year. Overall, Ipca Labs has shown resilience and growth in its financial performance over the years.

Should I buy, sell or hold Ipca Labs?

Is Ipca Labs technically bullish or bearish?

As of December 1, 2025, the technical trend for Ipca Labs is mildly bearish, influenced by weak daily moving averages and monthly indicators, despite a bullish weekly MACD and mildly bullish Bollinger Bands.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating weakness and the monthly MACD showing a mildly bearish outlook. While the weekly MACD is bullish, the overall sentiment is tempered by the monthly indicators, including the KST and Dow Theory, which are also mildly bearish. The Bollinger Bands present a mildly bullish signal on both weekly and monthly time frames, but this is overshadowed by the bearish signals in moving averages and the lack of strong momentum in the RSI. Overall, the technical indicators suggest a cautious approach in the current market environment for Ipca Labs.

Which are the latest news on Ipca Labs?

Why is Ipca Labs falling/rising?

As of 03-Dec, the stock price of Ipca Laboratories Ltd is 1,427.85, showing a slight decline today but positive trends over the past week and month. Despite a year-to-date drop of -15.59%, strong fundamentals and a favorable PEG ratio indicate potential for future recovery.

As of 03-Dec, the stock price of Ipca Laboratories Ltd is currently at 1,427.85, reflecting a slight decline of -0.55 (-0.04%). Despite this minor decrease, the stock has shown positive performance trends over various periods. For instance, in the past week, the stock has risen by 1.49%, outperforming the Sensex, which has fallen by 0.59%. Over the last month, Ipca Labs has increased by 9.00%, while the Sensex has only gained 1.34%. <BR><BR>However, the year-to-date performance indicates a significant decline of -15.59% for Ipca Labs, contrasting with the Sensex's increase of 8.92%. This longer-term perspective shows that while the stock has had recent positive movements, it has struggled overall this year. <BR><BR>Today's trading performance is described as inline with the sector, and the stock is currently trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend in the short to medium term. Nevertheless, there has been a noted decrease in investor participation, with delivery volume falling by 0.95% compared to the 5-day average, which could be contributing to the current price decline.<BR><BR>On a positive note, the company has demonstrated strong fundamentals, including a low debt-to-equity ratio, a significant growth in operating profit, and consistent positive results over the last six quarters. The stock is also trading at a discount compared to its peers, with a PEG ratio of 0.6, suggesting that it may be undervalued relative to its earnings growth potential. High institutional holdings at 47.2% further support the stock's stability, as these investors typically have better resources for analyzing company fundamentals.<BR><BR>In summary, while the stock is experiencing a slight decline today, its recent performance trends and strong fundamentals suggest that it may have the potential for recovery in the future.